Drug

Esketamine

Established medicine

ClassGlutamate [NMDA] receptor negative allosteric modulatorResearchOngoing clinical research

Also known as (-)-Ketamine, (S)-(-)-ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, (S)-ketamine+6 more

(-)-Ketamine, (S)-(-)-ketamine, (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone, (S)-ketamine, L-ketamine, S-(-)-Ketamine, S-ketamine, Spravato, s(+)ketamine, Esketamina.

RxNorm2119365 ChEMBLCHEMBL395091 ATCN06AX27 ATCN01AX14UNII50LFG02TXD

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or Behavior

Clinical trial2026-07-06Results expected Q2 2031 · ClinicalTrials.gov

A Clinical Study of Esketamine for Sedation, Delirium Prevention and Clinical Outcomes in Septic Patients Under Invasive Mechanical Ventilation

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Effect of Intravenous Infusion of Esketamine Combined Pulsed Radiofrequency on Acute/Subacute Zoster-associated Trigeminal Neuralgia

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Effects of Single Dose of Ayahuasca or Esketamine on Posttraumatic Stress Disorder: a Randomized, Double-blinded Study

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities

Clinical trial2026-06-30Results expected Q4 2028 · ClinicalTrials.gov

Effect of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Oral and Maxillofacial Surgery: A Prospective, Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial

Clinical trial2026-06-24Results expected Q1 2027 · ClinicalTrials.gov

Propofol, Dexmedetomidine, and Esketamine-Induced Unresponsive States: Alterations in Information Integration and Brain Networks

Clinical trial2026-06-12Results expected Q3 2026 · ClinicalTrials.gov

An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of Esketamine Nasal Spray in Korean Participants With Treatment-Resistant Depression(TRD)

Clinical trial2026-06-05Results expected Q2 2027 · ClinicalTrials.gov

The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Open Thyroid Surgery: A Randomized Controlled Study

Clinical trial2026-06-04Results expected Q2 2027 · ClinicalTrials.gov

Effects of Perioperative Intravenous Infusion Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy: A 2×2 Factorial Randomized Controlled Trial

Clinical trial2026-06-01Completed · ClinicalTrials.gov

Effects of a Single Dose of Ayahuasca or Esketamine on Body Image Perception in Women: a Randomized, Double-blind Study

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

Effects of a Single Dose of Ayahuasca or Esketamine on the Menstrual Cycle and Premenstrual Symptoms: a Randomized, Double-Blind Study

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Esketamine

Aliases & brands

(-)-Ketamine(S)-(-)-ketamine(S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone(S)-ketamineL-ketamineS-(-)-KetamineS-ketamineSpravatos(+)ketamineEsketamina

RxNorm CUI

2119365

ChEMBL ID

CHEMBL395091

ATC codes

N06AX27N01AX14

UNII

50LFG02TXD

Primary mechanism

Glutamate [NMDA] receptor negative allosteric modulator

Pharmacology & targets

7 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Glutamate receptor ionotropic, NMDA 1

GRIN1 · Q05586